164 related articles for article (PubMed ID: 35716453)
1. Cancer treatment-related cardiac dysfunction in breast cancer survivors: A retrospective descriptive study using electronic health records from a Korean tertiary hospital.
Lim A; Jang H; Jeon M; Fadol AP; Kim S
Eur J Oncol Nurs; 2022 Aug; 59():102163. PubMed ID: 35716453
[TBL] [Abstract][Full Text] [Related]
2. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
5. Activation recovery interval as an electrocardiographic repolarization index to detect doxorubicin-induced cardiotoxicity.
Kinoshita T; Onda N; Ohno R; Ikeda T; Sugizaki Y; Ohara H; Nakagami T; Yuzawa H; Shimada H; Shimizu K; Ikeda T
J Cardiol; 2023 Dec; 82(6):473-480. PubMed ID: 37506822
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
7. The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review.
Murray J; Bennett H; Bezak E; Perry R
Eur J Prev Cardiol; 2022 Mar; 29(3):463-472. PubMed ID: 33693524
[TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
9. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity evaluation using magnetic resonance imaging in breast Cancer patients (CareBest): study protocol for a prospective trial.
Hong YJ; Kim GM; Han K; Kim PK; Lee SA; An E; Lee JY; Lee HJ; Hur J; Kim YJ; Kim MJ; Choi BW
BMC Cardiovasc Disord; 2020 Jun; 20(1):264. PubMed ID: 32493217
[TBL] [Abstract][Full Text] [Related]
12. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
[TBL] [Abstract][Full Text] [Related]
13. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications.
Bikiewicz A; Banach M; von Haehling S; Maciejewski M; Bielecka-Dabrowa A
ESC Heart Fail; 2021 Aug; 8(4):2397-2418. PubMed ID: 33955207
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
16. Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy.
Jones KA; Small AD; Ray S; Hamilton DJ; Martin W; Robinson J; Goodfield NER; Paterson CA
J Nucl Cardiol; 2022 Apr; 29(2):581-589. PubMed ID: 32748278
[TBL] [Abstract][Full Text] [Related]
17. Cardiac dysfunction and their determinants in patients treated for breast cancer and lymphoma: A cardio-oncology center experience.
Khaled S; Abdelkhalek S; Aljuwaybiri R; Almatrafi J; AlHarbi A; Almarhabi R; Alyamani F; Soliman M; Jubran E; Shalaby G
Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102187. PubMed ID: 37913931
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
Bouwer NI; Steenbruggen TG; van Rosmalen J; Rier HN; Kitzen JJEM; van Bekkum ML; Tije AJT; de Jong PC; Drooger JC; Holterhues C; Smorenburg CH; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
Breast Cancer Res Treat; 2021 Apr; 186(3):851-862. PubMed ID: 33394273
[TBL] [Abstract][Full Text] [Related]
19. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
[TBL] [Abstract][Full Text] [Related]
20. Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation.
Peleg Hasson S; Arnold J; Merdler I; Sivan A; Shamai S; Geva R; Merimsky O; Shachar E; Waissengrin B; Moshkovits Y; Arbel Y; Topilsky Y; Rozenbaum Z; Wolf I; Laufer-Perl M
J Immunother; 2021 Jun; 44(5):179-184. PubMed ID: 33950028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]